Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving hundreds of leading biopharmaceutical companies globally:

McKinsey
Citi
UBS
Healthtrust
Daiichi Sankyo
McKesson

Generated: September 15, 2019

DrugPatentWatch Database Preview

Patent: 8,668,914

  Try a free trial


See Plans and Pricing

« Back to Dashboard

Summary for Patent: 8,668,914
Title:Use of equol for treating skin diseases
Abstract: Equol (7-hydroxy-3(4\'hydroxyphenyl)-chroman), the major metabolite of the phytoestrogen daidzein, specifically binds and blocks the hormonal action of 5.alpha.-dihydrotestosterone (DHT) in vitro and in vivo. Equol can bind circulating free DHT and sequester it from the androgen receptor, thus altering growth and physiological hormone responses that are regulated by androgens. These data suggest a novel model to explain equol\'s biological properties. The significance of equol\'s ability to specifically bind and sequester DHT from the androgen receptor have important ramifications in health and disease and may indicate a broad and important usage for equol in the treatment and prevention of androgen-mediated pathologies of skin and hair. Thus, equol can specifically bind DHT and prevent DHT\'s biological actions in physiological and pathophysiological processes affecting skin and hair.
Inventor(s): Lephart; Edwin Douglas (Orem, UT), Lund; Trent D. (St. Charles, IL), Setchell; Kenneth David Reginald (Cincinnati, OH), Handa; Robert J. (Phoenix, AZ)
Assignee: Brigham Young University (Provo, UT) Colorado State University Research Foundation (Fort Collins, CO) Children\'s Hospital Medical Center (Cincinnati, OH)
Application Number:12/533,169
Patent Claims:see list of patent claims

Details for Patent 8,668,914

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Advance Biofactures SANTYL collagenase VIAL 101995 001 1965-06-04 ➤ Sign Up Brigham Young University (Provo, UT) Colorado State University Research Foundation (Fort Collins, CO) Children\'s Hospital Medical Center (Cincinnati, OH) 2022-07-24 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Subscribe to access the full database, or try a Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Cantor Fitzgerald
QuintilesIMS
Merck
Julphar
AstraZeneca
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.